These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24667722)

  • 21. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
    Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
    Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH; Kang MJ; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim SB
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
    Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
    J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
    Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
    Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
    Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
    Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Lambertini M; Martel S; Campbell C; Guillaume S; Hilbers FS; Schuehly U; Korde L; Azim HA; Di Cosimo S; Tenglin RC; Huober J; Baselga J; Moreno-Aspitia A; Piccart-Gebhart M; Gelber RD; de Azambuja E; Ignatiadis M
    Cancer; 2019 Jan; 125(2):307-316. PubMed ID: 30335191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
    Venet D; Rediti M; Maetens M; Fumagalli D; Brown DN; Majjaj S; Salgado R; Pusztai L; Harbeck N; El-Abed S; Wang Y; Saura C; Gomez H; Semiglazov VF; de Azambuja E; Huober J; Nuciforo P; Di Cosimo S; Piccart M; Loi S; Rothé F; Sotiriou C
    Clin Cancer Res; 2021 Oct; 27(20):5607-5618. PubMed ID: 34321278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
    JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
    Man VC; Cheung PS
    Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
    Azim HA; Rothé F; Aura CM; Bavington M; Maetens M; Rouas G; Gebhart G; Gamez C; Eidtmann H; Baselga J; Piccart-Gebhart M; Ellis C; Vuylsteke P; Cure H; Domont J; Ferro A; Toral-Peña JC; de Azambuja E; Sotiriou C; Di Cosimo S; Ignatiadis M
    Breast; 2013 Dec; 22(6):1060-5. PubMed ID: 24060577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
    Jackisch C; Cortazar P; Geyer CE; Gianni L; Gligorov J; Machackova Z; Perez EA; Schneeweiss A; Tolaney SM; Untch M; Wardley A; Piccart M
    Cancer Treat Rev; 2021 Sep; 99():102229. PubMed ID: 34139476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Receptor Status on Mastectomy and Contralateral Prophylactic Mastectomy Rates in Early Stage Invasive Breast Carcinoma.
    Dutta SW; Trifiletti DM; Grover S; Romano KD; Janowski EM; Showalter SL
    Clin Breast Cancer; 2018 Apr; 18(2):121-127. PubMed ID: 28811185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department].
    Nakada T; Hosono Y
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1504-1506. PubMed ID: 30382059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer.
    Spanheimer PM; Carr JC; Thomas A; Sugg SL; Scott-Conner CE; Liao J; Weigel RJ
    Am J Surg; 2013 Jul; 206(1):2-7. PubMed ID: 23375759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.